LYVFIRLA Trademark

Trademark Overview

On Monday, April 20, 2020, a trademark application was filed for LYVFIRLA with the United States Patent and Trademark Office. The USPTO has given the LYVFIRLA trademark a serial number of 88878536. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, June 20, 2022. This trademark is owned by Intercept Pharmaceuticals, Inc.. The LYVFIRLA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, therapeutic bile acid analogues; pharmaceutical preparations for the treatment of liver diseases, disorders and conditions; pharmaceuticals for treating nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, liver fibrosis, and liver cirrhosis
lyvfirla

General Information

Serial Number88878536
Word MarkLYVFIRLA
Filing DateMonday, April 20, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, June 20, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 22, 2020

Trademark Statements

Goods and ServicesPharmaceutical preparations, namely, therapeutic bile acid analogues; pharmaceutical preparations for the treatment of liver diseases, disorders and conditions; pharmaceuticals for treating nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, liver fibrosis, and liver cirrhosis

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, April 28, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameIntercept Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressMorristown, NJ 07960
Party NameIntercept Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10001

Trademark Events

Event DateEvent Description
Tuesday, June 21, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, June 20, 2022ABANDONMENT - NO USE STATEMENT FILED
Monday, March 21, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, March 21, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, March 21, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, March 21, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, March 21, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, November 19, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 17, 2021SOU EXTENSION 2 GRANTED
Wednesday, November 17, 2021SOU EXTENSION 2 FILED
Wednesday, November 17, 2021SOU TEAS EXTENSION RECEIVED
Thursday, July 15, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, July 15, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, July 15, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, April 29, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, April 27, 2021SOU EXTENSION 1 GRANTED
Tuesday, April 27, 2021SOU EXTENSION 1 FILED
Tuesday, April 27, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, November 17, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 22, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 22, 2020PUBLISHED FOR OPPOSITION
Wednesday, September 2, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, August 14, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, August 12, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, August 12, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, August 7, 2020ASSIGNED TO LIE
Wednesday, July 22, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, July 17, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, July 17, 2020NON-FINAL ACTION E-MAILED
Friday, July 17, 2020NON-FINAL ACTION WRITTEN
Monday, July 13, 2020ASSIGNED TO EXAMINER
Tuesday, April 28, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, April 23, 2020NEW APPLICATION ENTERED

Related Keywords

lyvfirla liver pharmaceutical preparations nonalcoholic treating steatohepatitis fatty cirrhosis fibrosis disease